Atorvastatin ameliorated PM_2.5-induced atherosclerosis in rats

References

• Gakidou E, Afshin A, Abajobir AA, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the global burden of disease study 2016. The Lancet. 2017;390(10100):1345–1422. doi:10.1016/S0140-6736(17)32366-8.
   PubMed Web of Science ®Google Scholar
• Newby DE, Mannucci PM, Tell GS, ESC Heart Failure Association, et al. Expert position paper on air pollution and cardiovascular disease. Eur Heart J. 2015;36(2):83–93.
   PubMed Web of Science ®Google Scholar
• Wang C, Tu Y, Yu Z, Lu R. PM2.5 and cardiovascular diseases in the elderly: an overview. Int J Environ Res Public Health. 2015;12(7):8187–8197. doi:10.3390/ijerph120708187.
   PubMed Web of Science ®Google Scholar
• Brauer M, Freedman G, Frostad J, et al. Ambient air pollution exposure estimation for the global burden of disease 2013. Environ Sci Technol. 2016;50(1):79–88. doi:10.1021/acs.est.5b03709.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhao Z, Pang X, et al. Genistein protects against Ox-LDL-induced inflammation through MicroRNA-155/SOCS1-mediated repression of NF-kB signaling pathway in HUVECs. Inflammation. 2017;40(4):1450–1459.
   PubMed Web of Science ®Google Scholar
• Kojima M, Ozawa N, Mori Y, et al. Catestatin prevents macrophage-driven atherosclerosis but not arterial injury-induced neointimal hyperplasia. Thromb Haemost. 2018;118(1):182–194.
   PubMed Web of Science ®Google Scholar
• Yatera K, Hsieh J, Hogg JC, et al. Particulate matter air pollution exposure promotes recruitment of monocytes into atherosclerotic plaques. Am J Physiol Heart Circ Physiol. 2008;294(2):H944–53.
   PubMed Web of Science ®Google Scholar
• Geng J, Liu H, Ge P, et al. PM2.5 promotes plaque vulnerability at different stages of atherosclerosis and the formation of foam cells via TLR4/MyD88/NFkappaB pathway. Ecotoxicol Environ Saf. 2019;176:76–84.
   PubMed Web of Science ®Google Scholar
• Chen H, Burnett RT, Copes R, et al. Ambient fine particulate matter and mortality among survivors of myocardial infarction: population-based cohort study. Environ Health Perspect. 2016;124(9):1421–1428.
   PubMed Web of Science ®Google Scholar
• Du X, Jiang S, Zeng X, et al. Air pollution is associated with the development of atherosclerosis via the cooperation of CD36 and NLRP3 inflammasome in ApoE(-/-) mice. Toxicol Lett. 2018;290:123–132.
   PubMed Web of Science ®Google Scholar
• Shahraeini SS, Akbari J, Saeedi M, et al. Atorvastatin solid lipid nanoparticles as a promising approach for dermal delivery and an anti-inflammatory agent. AAPS PharmSciTech. 2020;21(7):263. doi:10.1208/s12249-020-01807-9.
   PubMed Web of Science ®Google Scholar
• Wu L, Cheng Y, Peng S, Zhang W, Zhang C. Sphingosine kinase 1 plays an important role in atorvastatin-mediated anti-inflammatory effect against acute lung injury. Mediators Inflamm. 2021;2021:9247285.
   PubMed Web of Science ®Google Scholar
• Motevalian M, Tekyeh Maroof N, Nematollahi MH, Khajehasani F, Fatemi I. Atorvastatin modulates the expression of aging-related genes in the brain of aging induced by D-galactose in mice. Iran J Basic Med Sci. 2021;24(10):1388–1394. doi:10.22038/IJBMS.2021.58502.12996.
   PubMed Web of Science ®Google Scholar
• Jiang J, Liang S, Zhang J, et al. Melatonin ameliorates PM2.5 -induced cardiac perivascular fibrosis through regulating mitochondrial redox homeostasis. J Pineal Res. 2021;70(1):e12686. doi:10.1111/jpi.12686.
   PubMed Web of Science ®Google Scholar
• Wang S, Wang F, Yang L, et al. Effects of coal-fired PM2.5 on the expression levels of atherosclerosis-related proteins and the phosphorylation level of MAPK in ApoE(-/-) mice. BMC Pharmacol Toxicol. 2020;21(1):34.
   PubMed Web of Science ®Google Scholar
• Liu J, Sun Q, Sun M, et al. Melatonin alleviates PM2.5-triggered macrophage M1 polarization and atherosclerosis via regulating NOX2-mediated oxidative stress homeostasis. Free Radic Biol Med. 2022;181:166–179. doi:10.1016/j.freeradbiomed.2022.02.005.
   PubMed Web of Science ®Google Scholar
• Liu Y, Cheng P, Wu AH. Honokiol inhibits carotid artery atherosclerotic plaque formation by suppressing inflammation and oxidative stress. Aging (Albany NY). 2020;12(9):8016–8028. doi:10.18632/aging.103120.
   PubMedGoogle Scholar
• Morieri ML, Perrone V, Veronesi C, et al. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets’ attainment in subjects with and without type 2 diabetes. Cardiovasc Diabetol. 2021;20(1):144.
   PubMed Web of Science ®Google Scholar
• Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. J Am Coll Cardiol. 2021;77(11):1439–1450. doi:10.1016/j.jacc.2021.01.027.
   PubMed Web of Science ®Google Scholar
• Feldt M, Menard J, Rosendahl AH, et al. The effect of statin treatment on intratumoral cholesterol levels and LDL receptor expression: a window-of-opportunity breast cancer trial. Cancer Metab. 2020;8(1):25. doi:10.1186/s40170-020-00231-8.
   PubMed Web of Science ®Google Scholar
• Adams A, Bojara W, Romanens M. Effect of statin treatment in patients with advanced carotid atherosclerosis: an observational outcome study. Cardiol Res. 2021;12(6):335–339. doi:10.14740/cr1318.
   PubMed Web of Science ®Google Scholar
• Yao T, Lu W, Ke J, et al. Residual risk of coronary atherosclerotic heart disease and severity of coronary atherosclerosis assessed by ApoB and LDL-C in participants with statin treatment: a retrospective cohort study. Front Endocrinol (Lausanne). 2022;13:865863.
   PubMed Web of Science ®Google Scholar
• Zhou P, Wang Y, Sun J, Yu Y, Mossa-Basha M, Zhu C. Assessment of therapeutic response to statin therapy in patients with intracranial or extracranial carotid atherosclerosis by vessel wall MRI: a systematic review and updated meta-analysis. Front Cardiovasc Med. 2021;8:742935. doi:10.3389/fcvm.2021.742935.
   PubMed Web of Science ®Google Scholar
• Arafa MH, Mohammad NS, Atteia HH. Rho-kinase inhibitors ameliorate diclofenac-induced cardiotoxicity in chloroquine-treated adjuvant arthritic rats. Life Sci. 2020;254:117605. doi:10.1016/j.lfs.2020.117605.
   PubMed Web of Science ®Google Scholar
• Li X, Yang Y, Wang Z, et al. Targeting non-coding RNAs in unstable atherosclerotic plaques: mechanism, regulation, possibilities, and limitations. Int J Biol Sci. 2021;17(13):3413–3427.
   PubMed Web of Science ®Google Scholar
• Palinski W, Tsimikas S. Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol. 2002;13(6):1673–1681. doi:10.1097/01.asn.0000018400.39687.8c.
   PubMed Web of Science ®Google Scholar
• Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol. 1998;18(11):1671–1678.
   PubMed Web of Science ®Google Scholar